• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
  • Guide for Authors
  • Submit Manuscript
  • Reviewers
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
Afro-Egyptian Journal of Infectious and Endemic Diseases
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 11 (2021)
Issue Issue 1
Volume Volume 10 (2020)
Volume Volume 9 (2019)
Volume Volume 8 (2018)
Volume Volume 7 (2017)
Volume Volume 6 (2016)
Volume Volume 5 (2015)
Volume Volume 4 (2014)
Volume Volume 3 (2013)
Volume Volume 2 (2012)
Volume Volume 1 (2011)
Alavinejad, P., Seiedian, S., Ebadi borna, K., Hajiani, E., Lajmirnia, M., Hesam, S. (2021). Comparison of Furazolidone Versus Clarithromycin for Eradication of Helicobacter Pylori Infection: A ‎Randomized Multicenter Clinical Trial ‎. Afro-Egyptian Journal of Infectious and Endemic Diseases, 11(1), 44-50. doi: 10.21608/aeji.2021.50347.1117
Pezhman Alavinejad; Seyed Saeed Seiedian; Kave Ebadi borna; Eskandar Hajiani; Maryam Lajmirnia; Saeed Hesam. "Comparison of Furazolidone Versus Clarithromycin for Eradication of Helicobacter Pylori Infection: A ‎Randomized Multicenter Clinical Trial ‎". Afro-Egyptian Journal of Infectious and Endemic Diseases, 11, 1, 2021, 44-50. doi: 10.21608/aeji.2021.50347.1117
Alavinejad, P., Seiedian, S., Ebadi borna, K., Hajiani, E., Lajmirnia, M., Hesam, S. (2021). 'Comparison of Furazolidone Versus Clarithromycin for Eradication of Helicobacter Pylori Infection: A ‎Randomized Multicenter Clinical Trial ‎', Afro-Egyptian Journal of Infectious and Endemic Diseases, 11(1), pp. 44-50. doi: 10.21608/aeji.2021.50347.1117
Alavinejad, P., Seiedian, S., Ebadi borna, K., Hajiani, E., Lajmirnia, M., Hesam, S. Comparison of Furazolidone Versus Clarithromycin for Eradication of Helicobacter Pylori Infection: A ‎Randomized Multicenter Clinical Trial ‎. Afro-Egyptian Journal of Infectious and Endemic Diseases, 2021; 11(1): 44-50. doi: 10.21608/aeji.2021.50347.1117

Comparison of Furazolidone Versus Clarithromycin for Eradication of Helicobacter Pylori Infection: A ‎Randomized Multicenter Clinical Trial ‎

Article 7, Volume 11, Issue 1, March 2021, Page 44-50  XML PDF (290.54 K)
Document Type: Original Article
DOI: 10.21608/aeji.2021.50347.1117
Authors
Pezhman Alavinejad email orcid 1; Seyed Saeed Seiedian1; Kave Ebadi borna2; Eskandar Hajiani1; Maryam Lajmirnia1; Saeed Hesam3
1Alimentary Tract Research Center, Imam Khomeini Hospital Clinical Research ‎Development Unit, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
2GI ward, Ahvaz Amir-Almomenin Hospital, Ahvaz Iran ‎.
3Department of biostatics and epidemiology school of health, Ahvaz Jundishapur University ‎of medical sciences, Ahvaz, Iran ‎.
Abstract
Background and study aims‎: to evaluate efficacy of Furazolidone versus clarithromycin in quadruple therapy for eradication of ‎Helicobacter Pylori (HP) infection‎ ‎‎.
Patients and Method: During a period of six months, all of the cases with HP infection in 3 referral tertiary centers ‎included. The participants randomly allocate to receive either clarithromycin or Furazolidone base ‎quadruple regimen. For all of the participants pantoprazole continued for 4 more weeks and after 1 ‎to 2 weeks of off therapy, they underwent Urea Breath Test to prove eradication‎‎.
Results: Overall 386 patients included (165 male (42%), average age 44.2y).  They diagnosed as non-ulcer ‎dyspepsia (311 cases), peptic ulcer disease (34 cases) and intestinal metaplasia (45 cases). The ‎participants randomly allocated to groups A & B to receive either clarithromycin or Furazolidone.‎ In groups A and B, 80.9% & 82.1% of participants achieved eradication respectively (P = 0.819). ‎During study, there was not any major complication but 3.1% of participants in each group ‎reported minor side effects including bitter taste, Gastrointestinal (GI) upset, headache and or ‎vertigo. In sub group analysis, the eradication rate of clarithromycin among patients with non-ulcer ‎dyspepsia, peptic ulcer disease (PUD) and intestinal metaplasia were 80%, 100% & 55.6% ‎respectively. These figures in group B (Furazolidone) were 80.7%, 100% & 85.7% respectively ‎‎(P= 0.906, 0 & 0.162). Overall, there was no significant difference in success rate between ‎clarithromycin and Furazolidone but in cases with intestinal metaplasia, the positive results with ‎Furazolidone was more (85.7% vs. 55.6%)‎‎.
Conclusion: In areas with high rate of resistance to clarithromycin, Furazolidone could be a potential candidate ‎in HP eradication regimen and in cases with intestinal metaplasia; Furazolidone could be even ‎more efficient than clarithromycin‎‎.
Keywords
HP; eradication; Furazolidone; clarithromycin; quadruple therapy
Main Subjects
Gastroenetrology
Statistics
Article View: 61
PDF Download: 65
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Journal Management System. Designed by NotionWave.